Literature DB >> 25417943

Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes.

Hanne Mumm1, Dorte Møller Jensen, Jens Aage Sørensen, Lise Lotte Torvin Andersen, Pernille Ravn, Marianne Andersen, Dorte Glintborg.   

Abstract

OBJECTIVES: To investigate obstetric outcomes in Danish women with different phenotypes of polycystic ovary syndrome (PCOS) and isolated hyperandrogenism (HA) and describe the risk of adverse obstetric outcomes in women with PCOS and HA compared to controls.
DESIGN: Cohort study.
SETTING: Odense University Hospital, Denmark. POPULATION: Women with PCOS were identified prospectively starting in 1997. Singleton pregnancies in women with PCOS and HA during 2003-2011 were included (n = 199). A control group was matched to the patient cohort according to date of childbirth (n = 995).
METHODS: Data on clinical characteristics and obstetric outcomes were collected in patients with PCOS and HA and controls. In PCOS and HA, total and free testosterone, sex hormone binding globulin, and hemoglobin A1c were measured outside pregnancy. During pregnancy, oral glucose tolerance tests were performed in 39 patients and 123 controls according to Danish national guidelines. PCOS phenotypes were based on the Rotterdam criteria. MAIN OUTCOME MEASURES: Gestational diabetes mellitus, pregnancy-induced hypertension, preeclampsia, delivery by emergency cesarean section, preterm delivery and anthropometric measures in the newborn.
RESULTS: The incidence of adverse obstetric outcomes and anthropometric measures among the newborns were comparable between different phenotypes of PCOS and patients with HA. In the oral glucose tolerance test, patients had a higher risk of gestational diabetes mellitus compared with controls; the odds ratio (95% confidence interval) was 3.3 (1.5-6.9) after adjustment for age, parity, and body mass index (p = 0.002). The incidence of other adverse obstetric outcomes was similar in patients and controls.
CONCLUSIONS: Obstetric outcomes were comparable in women with different PCOS phenotypes.
© 2014 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Polycystic ovary syndrome; gestational diabetes mellitus; hemoglobin A1c; hyperandrogenism; obstetric outcomes; polycystic ovary syndrome phenotypes; testosterone

Mesh:

Substances:

Year:  2014        PMID: 25417943     DOI: 10.1111/aogs.12545

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

Review 1.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

2.  Promoter methylation of yes-associated protein (YAP1) gene in polycystic ovary syndrome.

Authors:  Li-Le Jiang; Juan-Ke Xie; Jin-Quan Cui; Duo Wei; Bao-Li Yin; Ya-Nan Zhang; Yuan-Hui Chen; Xiao Han; Qian Wang; Cui-Lian Zhang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  Polycystic ovary syndrome and risk factors for gestational diabetes.

Authors:  Sanna Mustaniemi; Marja Vääräsmäki; Johan G Eriksson; Mika Gissler; Hannele Laivuori; Hilkka Ijäs; Aini Bloigu; Eero Kajantie; Laure Morin-Papunen
Journal:  Endocr Connect       Date:  2018-06-01       Impact factor: 3.335

4.  The Association of Polycystic Ovary Syndrome and Gestational Hypertensive Disorders in a Diverse Community-Based Cohort.

Authors:  Diane Schneider; Joel R Gonzalez; Miya Yamamoto; Jingrong Yang; Joan C Lo
Journal:  J Pregnancy       Date:  2019-01-01

5.  Women with PCOS with a History of Early Pregnancy Loss Show a Higher Risk of Gestational Diabetes Mellitus.

Authors:  Xian Liu; Lei Wang; Xiaohang Zuo; Chen Li; Yue Teng
Journal:  Int J Gen Med       Date:  2021-10-05

6.  Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome.

Authors:  Ketil Arne Espnes; Arne Hønnås; Tone S Løvvik; Per Ole M Gundersen; Audhild Naavik; Eirik Skogvoll; Andreas A Westin; Olav Spigset; Eszter Vanky
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-01-18       Impact factor: 3.688

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.